Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?

Maron DJ, Boden WE, Weintraub WS, Calfas KJ, O'Rourke RA.

Curr Treat Options Cardiovasc Med. 2011 Feb;13(1):16-25. doi: 10.1007/s11936-010-0104-7.

PMID:
21120640
2.

Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.

Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, Spertus JA, Dada M, Kostuk WJ, Knudtson M, Harris CL, Sedlis SP, Zoble RG, Title LM, Gosselin G, Nawaz S, Gau GT, Blaustein AS, Bates ER, Shaw LJ, Berman DS, Chaitman BR, Weintraub WS, Teo KK; COURAGE Trial Research Group.

J Am Coll Cardiol. 2010 Mar 30;55(13):1348-58. doi: 10.1016/j.jacc.2009.10.062.

3.

Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial.

Teo KK, Sedlis SP, Boden WE, O'Rourke RA, Maron DJ, Hartigan PM, Dada M, Gupta V, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

J Am Coll Cardiol. 2009 Sep 29;54(14):1303-8. doi: 10.1016/j.jacc.2009.07.013.

4.

Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE; COURAGE Investigators.

Circulation. 2008 Mar 11;117(10):1283-91. doi: 10.1161/CIRCULATIONAHA.107.743963. Epub 2008 Feb 11.

5.

Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.

Maron DJ, Spertus JA, Mancini GB, Hartigan PM, Sedlis SP, Bates ER, Kostuk WJ, Dada M, Berman DS, Shaw LJ, Chaitman BR, Teo KK, O'Rourke RA, Weintraub WS, Boden WE; COURAGE Trial Research Group.

Am J Cardiol. 2009 Oct 15;104(8):1055-62. doi: 10.1016/j.amjcard.2009.05.056. Epub 2009 Aug 28.

PMID:
19801024
6.

Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.

Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA.

JAMA. 2011 May 11;305(18):1882-9. doi: 10.1001/jama.2011.601. Erratum in: JAMA. 2011 Jun 15;305(23):2418.

PMID:
21558519
7.

Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.

Garg P, Wijeysundera HC, Yun L, Cantor WJ, Ko DT.

J Am Heart Assoc. 2014 Aug 13;3(4). pii: e000882. doi: 10.1161/JAHA.114.000882.

8.

Interpreting the results of the COURAGE trial: a non-interventionalist perspective.

Boden WE.

Rev Cardiovasc Med. 2009;10 Suppl 2:S34-44. Review.

PMID:
19898280
9.

Evolving concepts in selecting optimal strategies for the management of patients with stable coronary disease: pharmacologic or revascularization therapy.

Tandar A, Boden WE.

Curr Opin Cardiol. 2009 Nov;24(6):591-5. doi: 10.1097/HCO.0b013e32833155e2. Review.

PMID:
19752728
10.

Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial).

Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS; COURAGE Trial Investigators.

Am J Cardiol. 2009 Jul 1;104(1):1-4. doi: 10.1016/j.amjcard.2009.02.059. Epub 2009 Apr 16.

PMID:
19576311
11.

Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.

Fernandez SF, Boden WE.

Curr Atheroscler Rep. 2010 Nov;12(6):423-31. doi: 10.1007/s11883-010-0135-2. Review.

PMID:
20845088
12.

Placing COURAGE in context: review of the recent literature on managing stable coronary artery disease.

Coylewright M, Blumenthal RS, Post W.

Mayo Clin Proc. 2008 Jul;83(7):799-805. doi: 10.4065/83.7.799. Review.

PMID:
18613996
13.
14.

Risk factor control for coronary artery disease secondary prevention in large randomized trials.

Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V.

J Am Coll Cardiol. 2013 Apr 16;61(15):1607-15. doi: 10.1016/j.jacc.2013.01.044.

15.

Recent changes in practice of elective percutaneous coronary intervention for stable angina.

Ahmed B, Dauerman HL, Piper WD, Robb JF, Verlee MP, Ryan TJ Jr, Goldberg D, Boss RA Jr, Phillips WJ, Fedele F, Butzel D, Malenka DJ; Northern New England Cardiovascular Disease Study.

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):300-5. doi: 10.1161/CIRCOUTCOMES.110.957175. Epub 2011 Apr 19.

16.

Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.

Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, Bangalore S.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):476-90. doi: 10.1161/CIRCINTERVENTIONS.112.970954. Epub 2012 Aug 7. Review.

17.

Clinical implications of the BARI 2D and COURAGE trials: the evolving role of percutaneous coronary intervention.

Holper EM, Addo T.

Coron Artery Dis. 2010 Nov;21(7):397-401. doi: 10.1097/MCA.0b013e32833d0134. Review.

PMID:
20634692
18.

Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial).

Sedlis SP, Jurkovitz CT, Hartigan PM, Kolm P, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, Boden WE, Weintraub WS; COURAGE Study Investigators.

Am J Cardiol. 2013 Dec 1;112(11):1703-8. doi: 10.1016/j.amjcard.2013.07.034. Epub 2013 Sep 3.

PMID:
24011740
19.

Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease.

Sedlis SP, Jurkovitz CT, Hartigan PM, Goldfarb DS, Lorin JD, Dada M, Maron DJ, Spertus JA, Mancini GB, Teo KK, O'Rourke RA, Boden WE, Weintraub WS; COURAGE Study Investigators.

Am J Cardiol. 2009 Dec 15;104(12):1647-53. doi: 10.1016/j.amjcard.2009.07.043.

PMID:
19962469
20.

The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.

Zhang Z, Kolm P, Boden WE, Hartigan PM, Maron DJ, Spertus JA, O'Rourke RA, Shaw LJ, Sedlis SP, Mancini GB, Berman DS, Dada M, Teo KK, Weintraub WS.

Circ Cardiovasc Qual Outcomes. 2011 Mar;4(2):172-82. doi: 10.1161/CIRCOUTCOMES.110.940502. Epub 2011 Feb 8.

Supplemental Content

Support Center